Exposure-response analysis for spontaneously reported dizziness in pregabalin-treated patient with generalized anxiety disorder

Clinical Pharmacology and Therapeutics

Volumn 84, Issue 1, 2008, Pages 127-135

  Ito, K ^a   Hutmacher, M M ^a   Liu, J ^a   Qiu, R ^a   Frame, B ^a   Miller, R ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PREGABALIN;

ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DATA ANALYSIS; DISEASE SEVERITY; DIZZINESS; DRUG EXPOSURE; DRUG SAFETY; GENERALIZED ANXIETY DISORDER; HUMAN; INCIDENCE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; PREDICTION; PRIORITY JOURNAL; PROBABILITY; PROPORTIONAL HAZARDS MODEL;

ANXIETY DISORDERS; DIZZINESS; DOSE-RESPONSE RELATIONSHIP, DRUG; GAMMA-AMINOBUTYRIC ACID; HUMANS; MODELS, BIOLOGICAL; MODELS, STATISTICAL; MULTICENTER STUDIES AS TOPIC; PREDICTIVE VALUE OF TESTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 45549097053     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/sj.clpt.6100491     Document Type: Article

References (13)

1. Gee, N.S., Brown, J.P., Dissanayake, V.U., Offord, J., Thurlow, R. & Woodruff, G.N. The novel anticonvulsant drug, gabapentin (Neurontin), binds to the alpha2delta subunit of a calcium channel. J. Biol. Chem. 271, 5768-5776 (1996).
2. Fink, K. et al. Inhibition of neuronal Ca(2+) influx by gabapentin and pregabalin in the human neocortex. Neuropharmacology 42, 229-236 (2002).
3. Dooley, D.J., Mieske, C.A. & Borosky, S.A. Inhibition of K(+)-evoked glutamate release from rat neocortical and hippocampal slices by gabapentin. Neurosci. Lett. 280, 107-110 (2000).
4. Dooley, D.J., Donovan, C.M. & Pugsley, T.A. Stimulus-dependent modulation of [(3)H]norepinephrine release from rat neocortical slices by gabapentin and pregabalin. J. Pharmacol. Exp. Ther. 295, 1086-1093 (2000).
5. Maneuf, Y.P., Hughes, J. & McKnight, A.T. Gabapentin inhibits the substance P-facilitated K(+)-evoked release of [(3)H]glutamate from rat caudial trigeminal nucleus slices. Pain 93, 191-196 (2001).
6. Bialer, M., Johannessen, S.I., Kupferberg, H.J., Levy, R.H., Loiseau, P. & Perucca, E. Progress report on new antiepileptic drugs: a summary of the fourth Eilat conference (EILAT IV). Epilepsy Res. 34, 1-41 (1999).
7. Welty, D., Wang, Y., Busch, J.A., Taylor, C.P., Vartanian, M.G. & Radulovic, L.L. Pharmacokinetics (PK) and pharmacodynamics (PD) of CI-1008 (pregabalin) and gabapentin in rats with maximal electroshock [abstract]. Epilepsia, 38 Abstract 1.110 (1997).
8. Beal, S.L., Sheiner, L.B., eds. NONMEM User's Guides. (NONMEM Project Group, University of California, San Francisco, CA, 1992).
9. S-Plus 6.2 Professional Edition. (Insightful, Seattle, WA, 1988, 2003).
10. Kowalski, K.G., McFadyen, L., Hutmacher, M.M., Frame, B. & Miller, R. A two-part mixture model for longitudinal adverse event severity data. J. Pharmacokinet. Pharmacodyn. 30, 315-336 (2003).
11. Mandema, J.W. & Stanski, D.R. Population pharmacodynamic model for ketorolac analgesia. Clin. Pharmacol. Ther. 60, 619-635 (1996).
12. Gupta, S.K., Sathyan, G., Lindemulder, E.A., Ho, P.L., Sheiner, L.B. & Aarons, L. Quantitative characterization of therapeutic index: application of mixed-effects modeling to evaluate oxybutynin dose-efficacy and dose-side effect relationships. Clin. Pharmacol. Ther. 65, 672-684 (1999).
13. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER). FDA Guidance for Industry on "Population Pharmacokinetics" (1999).